1. Home
  2. LUCY vs GNPX Comparison

LUCY vs GNPX Comparison

Compare LUCY & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Eyewear Inc.

LUCY

Innovative Eyewear Inc.

HOLD

Current Price

$1.35

Market Cap

7.7M

Sector

Health Care

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.92

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUCY
GNPX
Founded
2017
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
6.5M
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
LUCY
GNPX
Price
$1.35
$1.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
251.5K
277.6K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,392,547.00
N/A
Revenue This Year
$80.76
N/A
Revenue Next Year
$210.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.22
N/A
52 Week Low
$1.29
$1.81
52 Week High
$7.08
$55.00

Technical Indicators

Market Signals
Indicator
LUCY
GNPX
Relative Strength Index (RSI) 40.79 32.08
Support Level $1.36 $2.51
Resistance Level $1.43 $3.68
Average True Range (ATR) 0.10 0.24
MACD -0.00 -0.09
Stochastic Oscillator 8.57 2.89

Price Performance

Historical Comparison
LUCY
GNPX

About LUCY Innovative Eyewear Inc.

Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: